Christian Martin Itin
Chief Executive Officer chez AUTOLUS THERAPEUTICS PLC
Fortune : 7 M $ au 31/03/2024
Profil
Christian Martin Itin is the founder of Zyomyx, Inc. (founded in 1998).
He is currently the Chief Executive Officer at Autolus Ltd.
(since 2021) and Autolus Therapeutics Plc (since 2021).
He also holds positions as a Non-Executive Director at Kymab Ltd., Director at Kymab Group Ltd., and Director at Autolus Holdings (UK) Ltd.
Dr. Itin previously served as the Chairman, CEO & Head-Media Relations at Cytos Biotechnology AG (2012-2016), Chief Executive Officer at Micromet AG (2006), President, Chief Executive Officer & Director at Amgen Rockville, Inc. (2011-2012), and Director at Kuros Biosciences Ltd.
(2018-2019).
He has also held the role of Non-Executive Director at Zyngenia, Inc. (2013-2014).
Dr. Itin obtained a doctorate degree from the University of Basel.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AUTOLUS THERAPEUTICS PLC
0,64% | 01/03/2023 | 1 066 009 ( 0,64% ) | 7 M $ | 31/03/2024 |
Postes actifs de Christian Martin Itin
| Sociétés | Poste | Début |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Chief Executive Officer | 01/03/2016 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Chief Executive Officer | 01/03/2016 |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 23/11/2016 |
Autolus Holdings (UK) Ltd.
 Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The private company is based in London, UK and was founded in 2018. | Director/Board Member | 15/06/2018 |
Anciens postes connus de Christian Martin Itin
| Sociétés | Poste | Fin |
|---|---|---|
| KUROS BIOSCIENCES AG | Chairman | 01/06/2018 |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Chief Executive Officer | 01/01/2016 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Chief Executive Officer | 02/03/2012 |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Chief Executive Officer | 01/05/2006 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Christian Martin Itin
| University of Basel | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KUROS BIOSCIENCES AG | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 9 |
|---|---|
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Health Technology |
Zyomyx, Inc.
 Zyomyx, Inc. Medical SpecialtiesHealth Technology Zyomyx, Inc. manufactured point-of-care diagnostic devices based on cell-counting technology. It engaged in the development and commercialization of diagnostic platforms. The firm offered disposable CD4 T-cell, a point-of-care test for HIV and AIDS treatment. The company was founded by Peter Wagner, Steffen Nock, Christian Itin, and Dana Ault-Riche in 1998 and was headquartered in Fremont, CA. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
Autolus Holdings (UK) Ltd.
Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The private company is based in London, UK and was founded in 2018. | Health Technology |
